• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Zofran (ondansetron hydrochloride) tablets, oral solution, and orally disintegrating tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2011

 

Summary View

WARNINGS

  • Information regarding post-marketing case reports of Torsade de Pointes
  • Recommendation to avoid use in patients with known congenital long QT syndrome
  • ECG monitoring recommendation in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation